Detail akcie GSK Rg online

Business Summary: GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Financial Summary: BRIEF: For the six months ended 30 June 2024, GSK plc revenues increased 8% to L15.25B. Net income decreased 29% to L2.22B. Revenues reflect US segment increase of 12% to L7.74B, Rest of world segment increase of 8% to L4.22B. Net income was offset by Other segment loss increase from L39M to L1.82B, Research and Development segment loss increase of 9% to L2.72B, Unallocated segment loss increase of 57% to L140M. Dividend per share increased from L0.28 to L0.30.